Asset Details
Do you wish to reserve the book?
Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study
Do you wish to request the book?
Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study
2020
Overview
Purpose
Anemia is common in oncology and negatively impacts quality of life. However, there is lack of knowledge about iron deficiency (ID) epidemiology. The aim of this study was to prospectively assess iron status in patients with locally advanced or metastatic cancer beginning chemotherapy.
Methods
In this prospective, multicenter cohort study, anemia and ID were evaluated in patients with locally advanced or metastatic solid tumors and lymphoma before starting chemotherapy. Blood samples were collected at inclusion (W0), 6 weeks (W6), and 12 weeks (W12). Prevalence was evaluated in the general population, according to tumor location and was correlated with tumor response.
Results
One hundred twenty-nine patients were enrolled between 2013 and 2015; 119 had solid tumors and 10 lymphomas. At W0, there were no significant difference between locations with a prevalence around 50–60% (range 47.2–70.4%) and only a trend for colorectal cancer (70.4%,
P
= 0.069) due to a higher prevalence of absolute ID (18.5%). Prevalence of ID+ decreased between W0 and W6 and remained stable until W12 due to the proportion of patients with ID and without anemia. However, anemia prevalence increased during W0 and W6 and remained stable to W6 from W12 due to patients with anemia but without ID. A significant correlation between tumor response and ID prevalence was found (
P
= 0.036).
Conclusions
We confirm the high prevalence of ID and anemia in cancer patients. ID status is correlated to tumor response providing a strong rationale for iron monitoring during cancer management.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Anemia
/ Anemia, Iron-Deficiency - blood
/ Anemia, Iron-Deficiency - chemically induced
/ Anemia, Iron-Deficiency - epidemiology
/ Cancer
/ Female
/ Humans
/ Iron
/ Iron Metabolism Disorders - blood
/ Iron Metabolism Disorders - chemically induced
/ Iron Metabolism Disorders - epidemiology
/ Lymphoma
/ Male
/ Medicine
/ Nursing
/ Oncology
/ Patients
/ Tumors
